Argos Therapeutics

Argos Therapeutics, Inc. is an immunotherapy company developing new treatments for cancer, infectious and autoimmune diseases and transplantation rejection. The Company is pioneering the development of individualized immunotherapy, using its combined mRNA and dendritic cell technology to deliver specifically targeted treatments, one patient at a time. Using material from both disease and blood samples collected from each patient, its Arcelis-based immunotherapies arm the patient’s dendritic cells to trigger a targeted patient-specific immune response.

Company Growth (employees)
Durham, US
Size (employees)
136 (est)
Argos Therapeutics was founded in 1997 and is headquartered in Durham, US

Argos Therapeutics Office Locations

Argos Therapeutics has an office in Durham
Durham, US (HQ)
4233 Technology Dr

Argos Therapeutics Data and Metrics

Argos Therapeutics Financial Metrics

Argos Therapeutics's revenue was reported to be $945.5 k in FY, 2016 which is a 82% increase from the previous period.

Revenue (FY, 2016)

945.5 k

Revenue growth (FY, 2015 - FY, 2016), %


Net income (FY, 2016)

(53 m)

EBIT (FY, 2016)

(52.3 m)

Market capitalization (27-Jun-2017)

15.7 m

Closing share price (27-Jun-2017)


Cash (31-Dec-2016)

53 m
Argos Therapeutics's current market capitalization is $15.7 m.
USDFY, 2014FY, 2015FY, 2016


2 m518.3 k945.5 k

Revenue growth, %


R&D expense

45.5 m62.1 m38.3 m

General and administrative expense

8.6 m11 m14.2 m

Operating expense total

54.1 m73.1 m53.3 m


(52.1 m)(72.5 m)(52.3 m)

EBIT margin, %


Interest expense

(1.1 m)(2.3 m)(1.8 m)

Interest income

66.6 k25.4 k57.3 k

Net Income

(53.3 m)(74.8 m)(53 m)
USDFY, 2014FY, 2015FY, 2016


37.2 m6.2 m53 m

Accounts Receivable

129 k73.8 k136.1 k

Current Assets

57.5 m8.8 m55.5 m


5.5 m22.3 m41 m

Total Assets

64.4 m31.1 m97.2 m

Accounts Payable

1.9 m2.9 m5.4 m

Current Liabilities

3.3 m8.2 m30.6 m

Additional Paid-in Capital

235.6 m250.9 m338.2 m

Retained Earnings

(204.2 m)(279 m)(332 m)

Total Equity

(28.2 m)

Financial Leverage

-1.1 x
USDFY, 2014FY, 2015FY, 2016

Net Income

(53.3 m)(74.8 m)(53 m)

Depreciation and Amortization

566.1 k680.4 k952.3 k

Accounts Receivable

(252 k)(629 k)(906 k)

Accounts Payable

543.4 k(137 k)1.2 m

Cash From Operating Activities

3.9 m(31.1 m)(40.7 m)

Purchases of PP&E

(1.1 m)(9.7 m)(15.3 m)

Cash From Investing Activities

(7.8 m)8.9 m(14.3 m)

Long-term Borrowings

(51.5 k)(35.5 k)(1.6 m)

Cash From Financing Activities

57 m21.1 m101.8 m

Interest Paid

307.9 k1.6 m2.4 m

Argos Therapeutics Market Value History

Argos Therapeutics Online and Social Media Presence

Argos Therapeutics Company Life and Culture

You may also be interested in